The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)

por Omar, Massar, Jensen, Jesper, Kistorp, Caroline, Højlund, Kurt, Videbæk, Lars, Tuxen, Christian, Larsen, Julie H., Andersen, Camilla F., Gustafsson, Finn, Køber, Lars, Schou, Morten, Møller, Jacob Eifer
Publicado 2022

Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)

por Pareek, Manan, Vaduganathan, Muthiah, Byrne, Christina, Mikkelsen, Astrid Duus, Kristensen, Anna Meta Dyrvig, Biering-Sørensen, Tor, Kragholm, Kristian Hay, Omar, Massar, Olsen, Michael Hecht, Bhatt, Deepak L
Publicado 2021

Pressure–flow responses to exercise in aortic stenosis, mitral regurgitation and diastolic dysfunction

por Andersen, Mads J, Wolsk, Emil, Bakkestrøm, Rine, Christensen, Nicolaj, Carter-Storch, Rasmus, Omar, Massar, Dahl, Jordi S, Frederiksen, Peter H, Borlaug, Barry, Gustafsson, Finn, Hassager, Christian, Moller, Jacob E
Publicado 2022

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

por Jensen, Jesper, Omar, Massar, Kistorp, Caroline, Poulsen, Mikael Kjær, Tuxen, Christian, Gustafsson, Ida, Køber, Lars, Gustafsson, Finn, Fosbøl, Emil, Bruun, Niels Eske, Videbæk, Lars, Frederiksen, Peter Hartmund, Møller, Jacob Eifer, Schou, Morten
Publicado 2019